Quanterix (QTRX) Aktievy
Quanterix Corporation, ett biovetenskapligt företag i Nordamerika, Europa, Mellanöstern, Afrika och Asien och Stillahavsområdet. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
QTRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Quanterix Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$2.56 |
| 52 veckors högsta | US$8.77 |
| 52 veckors lägsta | US$2.15 |
| Beta | 1.04 |
| 1 månads förändring | -1.16% |
| 3 månaders förändring | -16.34% |
| 1 års förändring | -48.49% |
| 3 års förändring | -90.13% |
| 5 års förändring | -94.61% |
| Förändring sedan börsintroduktionen | -85.35% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Sep 09
QTRX: Lowered Expectations And Coverage Milestones Will Shape Future Alzheimer’s Test Upside
Analysts have lowered their price targets on Quanterix to $3 from $4, citing weaker Q2 results, a significant guidance cut, and ongoing commercial execution challenges in softer academic, government, and pharma end markets. Analyst Commentary Recent commentary on Quanterix points to a cautious stance from research desks.Analysartikel • Aug 13
Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...Seeking Alpha • Aug 12
Quanterix: The Market Was Right To Lose Patience (Rating Downgrade)
Summary Quanterix (QTRX) is downgraded to Hold as its turnaround faces execution setbacks and delayed catalysts. Q2 revenue grew 34% but missed consensus, gross margins deteriorated and a $26.9M impairment raised even more concerns. Management cut 2026 revenue guidance and now expects cash flow breakeven in 2027, not 2026, undermining my prior bullish thesis. Commercial reorganization is underway, but meaningful improvement is deferred, increasing risk despite a lower valuation post-selloff. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 12
QTRX: Revised 2026 Guidance And Index Removal Will Support Stronger Earnings Power
Analysts have lowered their Quanterix price targets from about $4 to roughly $3, citing a weak Q2, a significant guidance cut, and ongoing challenges in end markets and commercial execution. What’s in the News for Quanterix Quanterix issued new guidance for the third quarter of 2026 and expects revenue to be flat to slightly above the second quarter level.Recent updates
Uppdatering av berättelse • Sep 09
QTRX: Lowered Expectations And Coverage Milestones Will Shape Future Alzheimer’s Test Upside
Analysts have lowered their price targets on Quanterix to $3 from $4, citing weaker Q2 results, a significant guidance cut, and ongoing commercial execution challenges in softer academic, government, and pharma end markets. Analyst Commentary Recent commentary on Quanterix points to a cautious stance from research desks.Analysartikel • Aug 13
Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...Seeking Alpha • Aug 12
Quanterix: The Market Was Right To Lose Patience (Rating Downgrade)
Summary Quanterix (QTRX) is downgraded to Hold as its turnaround faces execution setbacks and delayed catalysts. Q2 revenue grew 34% but missed consensus, gross margins deteriorated and a $26.9M impairment raised even more concerns. Management cut 2026 revenue guidance and now expects cash flow breakeven in 2027, not 2026, undermining my prior bullish thesis. Commercial reorganization is underway, but meaningful improvement is deferred, increasing risk despite a lower valuation post-selloff. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 12
QTRX: Revised 2026 Guidance And Index Removal Will Support Stronger Earnings Power
Analysts have lowered their Quanterix price targets from about $4 to roughly $3, citing a weak Q2, a significant guidance cut, and ongoing challenges in end markets and commercial execution. What’s in the News for Quanterix Quanterix issued new guidance for the third quarter of 2026 and expects revenue to be flat to slightly above the second quarter level.Uppdatering av berättelse • Jul 08
QTRX: Recalibrated Expectations Will Shape Long Term Alzheimer’s Blood Test Upside
Analysts have trimmed their Quanterix price targets by a few dollars, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E. These factors collectively support a lower, but still supported, valuation range in the latest research.Uppdatering av berättelse • Jun 24
QTRX: Revised Models And 2026 Guidance Will Support Stronger Earnings Power
Analysts have reduced their Quanterix price targets by $3 to $4, citing updated fair value estimates, revised revenue growth expectations, and a lower future P/E assumption in their latest models. Analyst Commentary Recent commentary on Quanterix highlights that, even with lower price targets, some bullish analysts still see room for the stock to deliver on execution and growth expectations embedded in their updated models.
Uppdatering av berättelse • Jun 07
QTRX: Alzheimer’s Blood Test Progress Will Support Long-Term Upside Despite Recent Pessimism
Analysts have trimmed their Quanterix price targets by $3 to $4, citing updated views on the company that feed into slightly adjusted assumptions for discount rates, revenue growth, profit margins, and future P/E in the latest valuation work. Analyst Commentary Recent research updates reflect a more cautious tone around Quanterix, with bearish analysts trimming price targets by US$3 to US$4.Uppdatering av berättelse • May 24
QTRX: Alzheimer’s Blood Test Progress Will Underpin Long-Term Upside Despite Recent Caution
Analysts have reduced their price targets on Quanterix by $3 to $4, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E that point to a more measured outlook. Analyst Commentary Bearish analysts are reworking their fair value math on Quanterix, trimming price targets by US$3 to US$4 and signaling a more cautious stance on how the story could play out.Uppdatering av berättelse • May 01
QTRX: Alzheimer’s Blood Test Progress Will Support Long Term Upside Potential
Analysts have reduced their price target on Quanterix by $2, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that were reflected in recent Street research, including a $4 reduction highlighted by Canaccord. Analyst Commentary Recent research around the target cut focuses less on a single headline number and more on how updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E compare with execution risk.Uppdatering av berättelse • Apr 16
QTRX: Expanding Alzheimer’s Blood Screening Access Will Support Stronger Future Earnings Power
Narrative Update on Quanterix The latest analyst price target on Quanterix has been revised in line with updated assumptions for discount rate, revenue growth, profit margin, and future P/E, as analysts adjust their models to reflect a slightly different balance of growth expectations and risk. What's in the News Lucent Diagnostics partnered with Life Line Screening to offer a non-invasive blood based biomarker test for Alzheimer's disease nationally, with programs already underway in Florida, California, and Texas, using a mobile model that reaches community centers, churches, and senior centers (Client Announcements).Uppdatering av berättelse • Apr 02
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Analysts made a modest adjustment to their price target on Quanterix, trimming it by $0.10 to reflect slightly lower assumptions for revenue growth and profit margins, along with a somewhat higher expected future P/E and discount rate. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte, algorithmic blood test intended to aid in evaluating patients with cognitive symptoms for possible Alzheimer’s disease.Uppdatering av berättelse • Mar 19
QTRX: Alzheimer’s Blood Test Progress Will Support Stronger Earnings Power Ahead
Analysts have nudged their price target on Quanterix to $8.00 from $8.00, reflecting slightly updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, without a clear shift in overall valuation stance. What's in the News Quanterix issued earnings guidance for 2026, with expected revenues between US$169 million and US$174 million, providing a concrete management view of the top line for that year (Corporate guidance).Uppdatering av berättelse • Mar 04
QTRX: Alzheimer’s Blood Test Progress Will Shape Favorable Long Term Outlook
Analysts have made modest adjustments to their price targets on Quanterix, reflecting updated views on discount rates, revenue growth expectations, profit margins, and future P/E assumptions, while keeping their overall fair value estimate broadly in line with prior levels. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer's disease, supported by clinical evidence in over 1,800 symptomatic patients across three cohorts.Uppdatering av berättelse • Feb 18
QTRX: Alzheimer’s Blood Test Progress Will Drive Long-Term Upside Potential
Analysts have lifted their price target on Quanterix to $7.00 from $7.00, reflecting slight tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view essentially unchanged. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. FDA for a multi analyte algorithmic blood test for Alzheimer's disease, aiming to support evaluation of patients with cognitive symptoms using a non invasive, high performance diagnostic tool (Key Developments).Uppdatering av berättelse • Feb 04
QTRX: New Leadership And Neurodegenerative Pipeline Will Balance Near Term Multiple Risks
Narrative Update on Quanterix Analysts have lifted their fair value estimate for Quanterix from US$6.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that collectively support a higher long term price target range. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer’s disease, aimed at helping identify whether symptomatic patients are likely to have amyloid brain plaques using its Simoa technology and a panel of five biomarkers (p Tau 217, Ab42, Ab40, GFAP, NfL), supported by clinical evidence from more than 1,800 patients (Key Developments).Uppdatering av berättelse • Jan 21
QTRX: Future Leadership And Biomarker Data Will Shape Balanced 2025 Outlook
Analysts have raised their price target on Quanterix to 7.33 from 6.00 previously, reflecting updated fair value estimates based on adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News The board has appointed Everett Cunningham as Chief Executive Officer, effective January 19, 2026.Analysartikel • Jan 10
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation's ( NASDAQ:QTRX ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a buy right now...Uppdatering av berättelse • Jan 07
QTRX: Multiple Sclerosis Biomarker Validation Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Quanterix to US$8.00 from US$7.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A study published in the journal Brain validates multiplexed Simoa assays for GFAP and NfL as a complementary approach for monitoring Multiple Sclerosis disease activity and progression.Uppdatering av berättelse • Dec 23
QTRX: Elevated Multiple And Higher Discount Rate Will Pressure Prospects
Analysts have raised their price target on Quanterix by approximately 20 percent to around 6 dollars per share, citing a modestly higher fair value estimate, slightly stronger long term profitability assumptions, and a willingness to apply a richer future earnings multiple, despite trimming revenue growth expectations and using a higher discount rate. What's in the News Publication of a landmark Brain journal study validating Quanterix Simoa assays for GFAP and NfL as a complementary, two biomarker approach for comprehensive Multiple Sclerosis disease monitoring, covering both acute inflammatory activity and slow progression (Key Developments) Evidence that elevated serum GFAP levels are significantly associated with higher risk of progression independent of relapse activity, highlighting a major unmet therapeutic need in MS and expanding the clinical utility of Quanterix assays (Key Developments) Creation of large Simoa-based normative reference databases for GFAP and NfL, incorporating age, sex, and BMI, alongside a free online interpretive tool to support more precise, individualized MS risk assessment (Key Developments) Updated 2025 revenue guidance of 130 million to 135 million dollars, implying pro forma revenue of 165 million to 170 million dollars for the year if combined operations are assumed, with an expected GAAP gross margin of 45 percent to 47 percent (Key Developments) Valuation Changes Fair Value Estimate has risen modestly from approximately 5 dollars to 6.0 dollars per share.Analysartikel • Aug 28
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 29% Lower
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 29% after a relatively good period...Uppdatering av berättelse • Aug 15
Biomarker Diagnostics And Proteomics Will Shape Future Markets
Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.Analysartikel • Aug 10
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...Analysartikel • Jun 13
Even With A 33% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Those holding Quanterix Corporation ( NASDAQ:QTRX ) shares would be relieved that the share price has rebounded 33% in...Analysartikel • Apr 08
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 30% Lower
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 30% in the last...
Ny berättelse • Mar 28
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets.Seeking Alpha • Jan 11
Quanterix: Why Pursuing A Big Deal For Akoya?
Summary Quanterix's IPO in 2017 was highly speculative, with its Simoa technology promising ultra-sensitive diagnostics but accompanied by substantial operating losses and continued dilution. Despite revenue growth to $121 million in 2023, Quanterix still faces significant losses, and expects a $25-$30 million cash burn in 2024. Slower growth in 2024, compliance issues, and a controversial acquisition of Akoya Biosciences have pressured shares, raising concerns about combining two loss-making entities. The acquisition news led to a 20% share price drop, prompting a cautious outlook despite the potential synergies and growing revenue base. Read the full article on Seeking AlphaAnalysartikel • Nov 07
Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a really impressive month, gaining 36% after a shaky period...Analysartikel • Oct 17
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Aktieägarnas avkastning
| QTRX | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | -4.8% | -1.9% | -0.9% |
| 1Y | -48.5% | 25.4% | 13.9% |
Avkastning vs industri: QTRX presterade sämre än US Life Sciences branschen som gav 25.4 % under det senaste året.
Avkastning vs Marknaden: QTRX presterade sämre än US marknaden som gav 13.9 % under det senaste året.
Prisvolatilitet
| QTRX volatility | |
|---|---|
| QTRX Average Weekly Movement | 17.7% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabil aktiekurs: QTRX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: QTRX s veckovolatilitet ( 18% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2007 | 450 | Everett Cunningham | www.quanterix.com |
Quanterix Corporation, ett life science-företag i Nordamerika, Europa, Mellanöstern, Afrika och Asien och Stillahavsområdet. Företaget erbjuder HD-X-instrumentet, en plattform för proteindetektion, och SR-X-instrumentet som gör det möjligt för forskare att använda Simoa-detektion i ett utökat antal applikationer. Företaget erbjuder också SP-X-instrumentet som bygger på Simoa planar array-teknik för mätning av multiplexa kemiluminescerande immunoassays.
Quanterix Corporation Sammanfattning av grunderna
| QTRX grundläggande statistik | |
|---|---|
| Börsvärde | US$121.07m |
| Vinst(TTM) | -US$123.11m |
| Intäkter(TTM) | US$153.41m |
0.8x
P/S-förhållande-1.0x
P/E-förhållandeÄr QTRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| QTRX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$153.41m |
| Kostnad för intäkter | US$85.05m |
| Bruttovinst | US$68.36m |
| Övriga kostnader | US$191.47m |
| Intäkter | -US$123.11m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -2.60 |
| Bruttomarginal | 44.56% |
| Nettovinstmarginal | -80.25% |
| Skuld/egenkapitalförhållande | 0% |
Hur har QTRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/14 21:59 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Quanterix Corporation bevakas av 7 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |